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TO THE EDITOR
PSORS1 is the major susceptibility
locus for psoriasis. It spans B300 kb
and contains at least 11 genes, among
which HLA-C and CDSN (human cor-
neodesmosin) are the most strongly
associated with the disease. Recent
genome-wide linkage studies and re-
combinant ancestral haplotype map-
ping analyses support HLA-C as the
primary PSORS1 susceptibility gene
(Cw6 allele; for review, see Elder
et al., 2010). However, the results
regarding the minimal candidate region
for PSORS1 are divergent, and some of
them retain CDSN within the region
(Oka et al., 1999; Lench et al., 2005;
Orru` et al., 2005). Interestingly, CDSN
is the only PSORS1 gene to be specifi-
cally expressed in the terminally
differentiated keratinocytes. It encodes
corneodesmosin, an adhesive protein of
corneodesmosomes, the structures re-
sponsible for stratum corneum (SC)
cohesion (Jonca et al., 2010). CDSN
sequential proteolysis is a prerequisite
for desquamation. The essential role of
the protein was recently demonstrated
in the mouse, as inactivation of its gene
was lethal within a few hours after birth
(Matsumoto et al., 2008; Leclerc et al.,
2009), and in humans, as nonsense
CDSN mutations were shown to be
responsible for hypotrichosis simplex
of the scalp (MIM 146520; Levy-
Nissenbaum et al., 2003; Caubet et al.,
2010) and for peeling skin disease
(MIM 270300; Oji et al., 2010). More-
over, CDSN is highly polymorphic,
and, among the six more common haplo-
types defined by six non-synonymous
single-nucleotide polymorphisms (Guerrin
et al., 2001), haplotypes 1.11 and 1.21
were found to be overtransmitted and
defined as risk haplotypes for psoriasis
(Capon et al., 2003).
Degradation of the corneodesmo-
some proteins, including CDSN, by
serine proteases of the kallikrein (KLK)
family, mainly KLK7 and KLK5, is
thought to lead to desquamation (Jonca
et al., 2010). As hyperkeratosis and
abnormal desquamation are constant in
psoriasis, we assessed the putative
consequences of the various non-sy-
nonymous single-nucleotide poly-
morphisms on CDSN proteolysis. In
addition to KLKs, other classes of
proteases have been identified in the
SC, such as cysteine and aspartic
proteases, which may also be involved
in CDSN degradation and in the tightly
regulated process of desquamation
(Jonca et al., 2010). The CDSN variants
encoded by each of the six more
common haplotypes were produced as
recombinant proteins in COS-7 cells
and processed for in vitro proteolysis
experiments with several of these en-
zymes (Supplementary Materials and
Methods online). Compared with the
haplotype 1.11-encoded CDSN, chosen
as a reference, the CDSN variants
encoded by the haplotypes 1.41, 1.21,
1.52, and 2.11 differ in only one amino-
acid substitution (at positions 202, 401,
408, or 410, respectively), whereas the
haplotype 2.21-encoded CDSN differs in
three amino-acid substitutions (at posi-
tions 143, 410, and 527). To analyze
individually the consequences of each
of the six amino-acid substitutions on
the protein proteolysis, we produced
v442 and v1593, two CDSN variants
undescribed in humans, which differ
from the 1.11-CDSN by one amino-acid
substitution at positions 143 and 527,
respectively (Table 1 and Figure 1a).
We first compared the sensitivity of
the CDSN variants to KLK7 using
immunoblotting with the anti-CDSN
mAb G36-19 (Figure 1b, upper panel).
After a 15-minute incubation with the
protease, all the variants except the
haplotype 1.41-encoded CDSN pro-
duced a G36-19-immunoreactive frag-
ment of 31 kDa, progressively cleaved
to generate a smaller immunoreactive
polypeptide of 18 kDa. An additional
intermediate fragment of 25 kDa was
transiently detected with variant 1.21
and, to a lesser extent, with variants
v442 and v1593. With the 1.41-CDSN,
only the intermediate fragment of
25 kDa was detected, not the G36-19
immunoreactive fragment of 18 kDa.
This showed that the last proteolysis
step did not occur, and probably that a
KLK7 cleavage site was lacking. KLK7
belongs to the chymotrypsin family
and is specific to amino-acid residues
with aromatic side chains in the P1
position (Skytt et al., 1995): the amino-
acid substitution F/S (p.F202S), only
encoded by the haplotype 1.41, may
result in the disappearance of such a
cleavage site on the protein. When
immunoblotting was performed with
the antibodies B102115 and D472486,
and with the mAb F28-27, each being
specific to different domains of CDSN
(Figure 1a), a similar proteolysis profile
was observed for all the variants (Figure
1b lower panel and data not shown).
Altogether, the size of the proteolysis
fragments and the relative position of
the recognized epitopes evidence three
KLK7 cleavage sites on CDSN: one
between the epitope recognized by
B102115 and F202, a second just after
F202, and a third between the G36-19
and F28-27 epitopes.
We further analyzed the proteo-
lysis of the eight CDSN variants byAbbreviations: CDSN/CDSN, human corneodesmosin; KLK, kallikrein; SC, stratum corneum
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KLK5 and cathepsin D, and also by
a-chymotrypsin and trypsin, two pro-
teases closely related to KLK7 and
KLK5, respectively (Figure 1c–f and data
not shown). Except for a-chymotrypsin,
none of these proteases produced
any differences in proteolysis patterns
between the eight CDSN variants,
regardless of the anti-CDSN anti-
bodies used for detection of the proteo-
lytic fragments. Interestingly, when
the 1.41-variant was incubated with
a-chymotrypsin, the final proteolysis
step producing an 18-kDa fragment
recognized by G36-19 was greatly
reduced. Consistent with the fact that
both enzymes belong to the same
catalytic family, these results were
similar to those obtained with KLK7.
In conclusion, p.F202S reduced the
in vitro proteolysis of CDSN by KLK7
and the related a-chymotrypsin, show-
ing that one of the non-synonymous
single-nucleotide polymorphisms of the
CDSN alleles (SNP*619) does affect the
sensitivity of the protein to proteolysis.
However, globally, this study did not
provide a molecular basis for associ-
ation between risk haplotypes and
psoriasis, and is more consistent with
previous genetic information suggesting
that CDSN association with the disease
is secondary to linkage disequilibrium
with HLA-Cw6 (Nair et al., 2006).
Of course the results were obtained
in vitro with soluble recombinant
CDSNs, and possibly they do not reflect
the actual sensitivity of CDSN variants
to proteases when conformed and
interacting with the other corneodes-
mosome components in vivo. We have
previously reported a persistence of
unproteolysed CDSN in the upper SC
of psoriatic lesional and non-lesional
skin, in agreement with the persistence
of corneodesmosomes in the SC of
the hyperkeratotic psoriatic epidermis
(Simon et al., 2008). However, it is not
clear whether the reduced proteolysis
of CDSN observed in psoriatic skin
directly results from a modified
sensitivity to SC proteases or whether
it is an indirect consequence of a
modified environment in psoriatic skin,
leading to a disruption of the tightly
regulated protease/protease inhibitor
balance.
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Figure 1. Proteolysis of the corneodesmosin (CDSN) variants using kallikrein7 (KLK7), kallikrein5 (KLK5), cathepsin D, a-chymotrypsin, and trypsin. (a)
Schematic representation of the CDSN variants. The amino-acid substitutions encoded by the six non-synonymous single-nucleotide polymorphisms (asterisks),
the peptide signal (hatched box), the two glycine–serine-rich domains (dark gray boxes), and the epitopes recognized by the antibodies B102115, G36-19,
F28-27, and D472486 (black boxes) are represented. (b–f) The variants were incubated with KLK7 (b), KLK5 (c), cathepsin D (d), a-chymotrypsin (e), and trypsin
(f) for 15minutes to 2 hours, and without protease for 2 hours (lanes C), separated by SDS-PAGE, and detected by immunoblotting with the antibodies B102115,
G36-19, F28-27, and D472486, as mentioned. In the case of incubation with KLK7 and immunodetection with G36-19, results obtained for the eight variants are
shown. Otherwise, results obtained only for haplotype 1.11- and 1.41-encoded CDSN are shown as the representative proteolysis profile. In (c) and (f), dividing
white lines indicate that lanes that were not originally run next to each other have been juxtaposed in the figure.
Table 1. Characteristics of the eight CDSN variants
Non-synonymous SNPs1
Haplotype or variant 442 (143) 619 (202) 1215 (401) 1236 (408) 1243 (410) 1593 (527) Disease status2
1.113 g (S) t (F) a (S) t (S) c (S) g (D) Overtransmitted
V4424 a (R) t (F) a (S) t (S) c (S) g (D)
1.413 g (S) c (S) a (S) t (S) c (S) g (D) Neutral
1.213 g (S) t (F) g (G) t (S) c (S) g (D) Overtransmitted
1.523 g (S) t (F) a (S) g (A) c (S) g (D) Undertransmitted
2.113 g (S) t (F) a (S) t (S) t (L) g (D) Undertransmitted
V15934 g (S) t (F) a (S) t (S) c (S) a (R)
2.213 a (R) t (F) a (S) t (S) t (L) a (R) Undertransmitted
Abbreviations: CDSN, corneodesmosin; SNP, single-nucleotide polymorphism.
1For each position, the nucleotide and corresponding amino acid (in brackets) are indicated (according to GenBank accession number AF030130). Indicated
in bold when different from the reference haplotype 1.11.
2Disease status in a psoriasis family-based study on the UK population (Capon et al., 2003).
3Haplotype numbers are given according to the nomenclature proposed by Guerrin et al. (2001).
4Potential variants not described in literature.
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TO THE EDITOR
Being amenable to genetic modifica-
tion, mice are critical in vivo tools to
test the role of gene mutations in
malignant melanoma (MM) develop-
ment. They are the animal model of
choice for studying MM growth and
treatments either as autochthonous tu-
mors or as xenografts. However, adult
mice do not have epidermal melano-
cytes (MCs), and primary murine MMs
are usually dermal, reminiscent of hu-
man malignant blue nevi (see, e.g.,
Dhomen et al., 2009), animal type, or
nodular MM. In contrast, most human
MMs appear to originate in the epider-
mis, although they can progress to a
vertical growth phase and invade the
dermis. Although most murine MMs are
dermal, lesions from the hepatocyte
growth factor model often exhibit epi-
dermal ‘‘pagetoid’’ spread on the albino
(FVB) but not C57BL6 background
(Noonan et al., 2001; Florell et al.,
2007). Focal pagetoid spread is also seen
in PtenF/F::Tyr-CreERT2::LSL-BrafCA/wt mice
(Dankort et al., 2009).
One factor that differentiates mouse
from human skin is the expression of
KIT receptor ligand (KITL), highly ex-
pressed in the human but not murine
epidermis (Kunisada et al., 1998; Longley
and Carter, 1999). It is expressed in
76% of human MMs, not only in
adjacent keratinocytes, but also some-
times in the tumor cells (Giehl et al.,
2007). Mice with engineered keratinocyte
Kitl expression (K14-Kitl) have epidermal
MCs throughout life (Kunisada et al.,
1998). Remarkably, they do not
develop MMs even after chronic UVR
exposures (Yamazaki et al., 2004).
When crossed onto a DNA repair
defective (Xpa-null) background, they
developed lentigo-like lesions (Yama-
zaki et al., 2005) after a harsh chronic
UVR regimen. Although the physiolo-
gical relevance of this study is ques-
tionable, as many animals died from
severe sunburn, epidermal MMs did
develop. Recently, K14-Kitl mice were
crossed with animals carrying activa-
tion of the metabotropic glutamate
receptor-1 (Abdel-Daim et al., 2010),
but only dermal MMs were reported.
We previously reported the devel-
opment of dermal MMs in Arf/::Tyr-Abbreviations: MC, melanocyte; MM, malignant melanoma
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Development of Epidermal MMs in Mice
